Atrion Corp ATRI
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Allen, TX, 75002